Introduction
Esophageal adenocarcinoma (EAC) is associated with the sixth-highest cancer-related mortality and increasing incidences mainly in the Western World [
1,
2]. Curative treatment consists mostly of a multimodal therapy of esophageal en-bloc resection and perioperative radio-chemotherapy, but compared to other cancer entities the outcome is still poor with only 20% of patients in Western populations surviving for more than 5 years [
3‐
5].
There is a high need for new therapeutic approaches in treating this cancer [
6].
The interaction of tumor cells and associated immune compartment is supposed to play an important role in cancer progression. Mechanisms of immunosuppression within the tumor and its microenvironment are incompletely understood, although neoantigen loss and negative regulation by immune checkpoints are presumed to lead to dysfunction of specialized T-cells [
7,
8].
Immune checkpoint inhibitors (e.g. Pembrolizimab, Nivolumab) enhancing antitumor T-Cell activity through the inhibition of immune checkpoints, like the programmed death-1 (PD-1) receptor [
9] and improved survival in some solid tumors like malignant melanoma and non-small cell lung carcinoma [
10‐
13]. First line and second line treatment of metastatic esophageal cancer with checkpoint inhibitors considering the PD1/PDL1 axis are currently tested in a Phase III evaluation with pembrolizumab (KEYNOTE-062, KEYNOTE-061) [
14] as well as nivolumab (CheckMate-577) in the adjuvant setting with various other approaches in all lines of therapy [
15].
Almost nothing is known about the precise composition of immune cells and their gene expression profiles in primary resected EACs and also nothing compared to neoadjuvant treated EACs.
Due to the fact that most EACs are neoadjuvantly treated, the question arises as to what effects neoadjuvant treatment has on the local immune micromileu in carcinoma?
Accordingly one aim of our study was to analyze and compare the immune profile of primary resected as well as neoadjuvant treated esophageal adenocarcinoma and to unravel possible targets for immunotherapy as for example cancer testis antigens (CTA) that have been shown to exhibit characteristics important for tumorigenesis. Targeting such antigens may control cancer progression [
16]. Additionally we compared the primary resected EACs in their regulation of genes known to be associated with response to PD-1/PD-L1 inhibitors. This so-called hot inflammation profile consists of 18 genes associated with a T cell-inflamed and IFN-γ-related response to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance [
17].
To address this question, we used the NanoString technology. Nanostring's panel-based gene expression platform, in particular, considers 770 genes that have been described as important in malignant tumors and their immune micromileu.
Discussion
Conventional oncological treatment regimens such as chemotherapy or radiotherapy are inadequate effective in EACs. Personalized therapy options are limited to HER2 blockage for a limited patient group showing a median advantage in progression-free survival of less than 3 months. Further therapy options are urgently needed.
Currently checkpoint-inhibitors like pembrolizumab and nivolumab which have proven to be effective, inter alia, in the treatment of malignant melanoma and NSCLCs are tested in different Phase III for esophageal cancer. First preliminary study results for pembrolizumab as a second-line treatment demonstrated an improved overall survival (OS) in patients with advanced or metastatic esophageal or esophagogastric junction carcinoma [
20].
The structure of the studies available to date illustrates a significant problem. The studies mimic gastric adenocarcinomas with the adenocarcinomas of the esophagus (and subsume these as adenocarcinomas of the gastroesophageal junction) in the erroneous assumption that there are no relevant differences in tumor biology. As a matter of fact gastric adenocarcinomas reveal just for immunotherapy relevant subgroups such as microsatellite-instability (MSI) and Epstein–Barr-virus-related (EBV) subgroup, which are exceedingly rare or missing in adenocarcinomas of the esophagus [
21,
22].
We have therefore focused on adenocarcinomas of the esophagus in this study.
The immune system interacts with esophageal adenocarcinomas in many ways and thereby substantially affects tumor progression and therapeutic response. Nearly nothing is known about these important interactions in EAC. Consequently the main focus of our study was to unravel the immune profile of EAC as defined by their T-cell activity, inflammation signature and immune escape mechanisms. Although most conventional therapies can elicit immune responses contributing to their efficacy, we could also show that radio-chemo therapy negatively alters the local immune status.
Other studies already identified molecular subtypes linked to the clinical outcome after immunotherapy. For example, different molecular subtypes have been identified in colorectal cancers which define potential strategies for immunotherapy [
23]. Multiple characteristics are proposed to be responsible for a certain immune microenvironment as well as related mechanisms of immune escape. The consensus molecular subtype I (CSM I) for colorectal carcinoma is characterized by a high expression of PD-1, CTLA-4, IDO1 and other immune checkpoints. Moreover, its immune regulation is mainly driven by the chemokine CXCR3/CCR5 axis and cytotoxic effector mechanisms that are critical for activation and differentiation of T cells. CSM type IV in contrast is definied by an increased TGF-b signaling and upregulated CXCL-12, which drive inflammation and metastasis formation. Upon our findings, that primary untreated patients with EACs showed a high expression of major immune checkpoints as well as an upregulated CXCR3/CCR5 axis, it would be interesting to define prognostic phenotypes and thereby directing therapeutic strategies. In addition to this, we identified a subgroup of EAC patients with ultra-high expression of cancer testis antigens (CTAs), which displayed a significant upregulation of genes associated with tumor progression and metastasis formation. We therefore suspect, the score of CTAs to be a possible prognostic marker for clinical outcome in EAC as already identified for other tumor entities [
16].
So far, neoadjuvant radiochemotherapy (RCT) is a well-established first-line treatment in patients with esophageal cancer. Nevertheless we here observed a significant decrease of T cell activity as measured by CD3 and CD8 expression after RCT. This finding implies that RCT impairs lymphocyte activity as well as components of the adaptive immune response, as targets of immunotherapy. Since the composition of the tumor microenvironment with immune cells and chemokines mainly drives efficacy of immunotherapy [
24] and RCT profoundly suppresses the adaptive immune response, we propose that a combination of both could be restricted. Similar observations have been made in cervical and colorectal cancer patients [
25,
26].
Restricting, however, we must state at this point that this explanation refers only to the local tumor micromileu. Memory cells in surrounding lymph nodes could trigger an effective neoantigen-driven tumor cell-destroying inflammatory response regardless of the local situation. Further it has to be kept in mind that the patient cohort of NACT-treated EAC includes only a small sample size. Nevertheless, these results can be an argument for clinical trials considering the use of checkpoint inhibitors first-line. We therefore propose to further validate the above described findings in future studies.
Controversely, we could not observe any upregulation of PD-1 expression upon chemotherapy as described previously [
25,
26]. This might be due to the fact, that primary esophageal tumor samples show no differential expression of PD-1 and PD-L1 at all. This evidence further suggests that PD-1 blocking agents, which have shown to be promising in NSCLC and renal cancer as well as melanoma, might not be as effective in esophageal adenocarcinoma or at least just in a small subset of patients with EACs. Nevertheless, recent clinical trials reveal efficacy of checkpoint inhibitors also in PD-L1 low expressing patients. This phenomenon is currently investigated [
27] and noteworthy within our study, other checkpoint molecules like HAVCR2 (TIM-3), LAG-3 and CTLA-4 are dominantly expressed and therefore promising therapy markers/targets (see discussion below). Furthermore most EACs show a high mutational burden (TMB) which is correlated with good clinical response to checkpoint inhibition in NSCLC. Interestingly, a family member of PD-1, CD276 that even elicits similar inhibitory effects on T-cells is dominantly upregulated in primary EAC. Recently, CD276, also known as B7-H3, was identified to decrease levels of IFN-y, TNF alpha and inflammatory cytokines and thereby allowing immune escape [
28].
Tumor escape from anti-tumor immunity is a critical event for tumor survival and progression [
29]. Different mechanisms have been described and discussed extensively in the past [
30,
31]. These include loss of antigenicity by modulation of the antigen presenting machinery. Downregulation of the antigen presenting MHC- class 1 has been found in various solid malignancies like melanoma, lung, breast and prostate cancers [
32]. Primary EAC samples within our study cohort display increased MHC class I expression on mRNA level compared to normal tissue. In contrast IHC screening identified approximately 30% of EAC to have a loss of MHC marker expression on their tumor cell surface. Nevertheless we could identify other inhibitors of MHC class I-linked macrophage phagocytosis on mRNA expression level. Interestingly the major receptor in detection and simultaneous inhibition of MHC class I triggered phagocytosis, LILRB1, was significantly upregulated and could explain a possible tumor escape mechanism [
33]. Further, tumors, which retain sufficient antigen presentation for immune recognition can still escape from elimination by downregulation of their immunogenicity, for example by the expression of immuno-inhibitory molecules (receptors and ligands) like PD-1/PD-L1, LAG3 and HAVCR2 (TIM-3) [
30]). Also the microenvironment with infiltrating tumor lymphocytes (TILs) and T cell suppressing enzymes enhances immunoresistance. The ability of tumors to orchestrate this surrounding environment determines the cellular fate of TILs and allows evasion from immune elimination [
34]. Enhancing efficacy of immunotherapy needs to consider immune escape mechanisms by immune profiling. Interestingly, within our cohort of primary naive esophageal carcinoma, distinct immune escape mechanisms are dominant, while others are not present. In detail, our cohort of primary EAC showed an upregulation of checkpoint inhibitors as most prominent mechanism of immune evasion with 7–4 fold increased expression of CTLA-4, HAVCR2 (TIM-3) and LAG3. Modulation of the tumor microenvironment as an enhancement of immunosuppression is prominent within primary naive EAC. We could identify high tumor inflammation signatures within nearly all patient samples compared to normal tissues. Approximately 50% of the samples elicit an extremely high score of inflammation markers. Furthermore, we could show a high CD38 expression within primary EAC, which was recently determined to be influenced by CD8 + T-cells within the tumor microenviroment and consequently correlates with the tumor inflammation signature [
35]. This further strengthens current approaches to combine anti-CD38 with checkpoint inhibitor therapy [
36]. Primary EAC, presenting a high inflammation signature in combination with dominant CD8 and CD38 expression might be promising targets for such a combinatorial treatment.
Recently, radiochemotherapy was thought to increase the presence of neoantigens as a result of its mutagenic character [
37]. In general, a greater overall survival as well as higher efficiency of immunotherapy with checkpoint inhibitors are associated with higher neoantigen burden and CD8 + T cell infiltration [
38]. Nevertheless, we identified that even the presence of cancer testis antigens is significantly decreased after radiochemotherapy in esophageal carcinoma. This is in concordance with another study conducted in ovarian cancer, where the authors found the predicted increase in neoantigens to be due to pre-existing mutational processes rather than from mutagenesis induced by chemotherapy [
38].
The present study demonstrated some important new findings: (a) the influence of the currently used neoadjuvant treatment, (b) the unexpected higher expression of checkpoint markers like LAG3, TIM-3, CTLA4 and CD276 in comparison to PD-L1/PD-1 supporting clinical trials analyzing the efficacy of a combination of different checkpoint inhibitors in EACs, (c) the importance of immune escape mechanism like a high CD38 or LILRB1 expression in EACs.
TIM-3, also known as HAVCR2 could be an interesting and promising target for anticancer immunotherapy, since it is expressed on a variety of T-cells, DCs (dendritic cells), macrophages and monocytes and elicits a strong innate anti-tumor immune response. A variety of different studies have proven comparable effects of anti TIM-3 inhibition [
39]. PD-1, TIM-3 and LAG-3 inhibitors are able to enhance the T-cell response to tumor antigens. Moreover a synergistic function of the above mentioned could enhance the response in combinatorial therapies [
40,
41]. LAG-3 as a further promising immune-checkpoint has been investigated in various clinical trials and combinatorial treatment with anti-PD1 therapy showed high efficacy especially in PD1 resistant settings [
40].
An increased expression of CD38 is correlated with a poor prognosis in chronic lymphocytic leukemia cells. Administration of the anti-CD38 mAb daratumumab has been shown to induce apoptosis and promotion of immune-initiated clearance [
42]. A combinatorial screening of PD1/PD-L1 and CD38 could be of interest for diagnostics to predict response to PD-L1 blockade or even allow for a combinatorial treatment with checkpoint inhibitors and CD38 blocking agents to improve patients’ outcome.
Furthermore to further identify prognostic markers, a clinical follow up of patients with different immunoprofiles could be of high interest. Additionally to the relative low sample size within the cohort of NACT-treated EACs, it has to be kept in mind that this group is heterogeneous according to the type of treatment regimen. To strengthen the findings described within this study, a larger and homogeneous cohort of NACT-trated EAC patients could be tested in future research. Although heterogeneity of this sub-chohort, the herein described major influences of treatment to the immune profile are similar regardless of treatment regimen. There is a difference between FLOT and CROSS treated patients on gene expression as described in Fig.
5, but the major influence of NACT treatment (a down-regulation of nearly all important checkpoint markers and inflammatory related genes in the local microenvironment) is consistent between both subgroups.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.